

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 215/36, A61K 31/47		A1	(11) International Publication Number: WO 97/44322 (43) International Publication Date: 27 November 1997 (27.11.97)												
<p>(21) International Application Number: PCT/GB97/01360</p> <p>(22) International Filing Date: 20 May 1997 (20.05.97)</p> <p>(30) Priority Data:</p> <table> <tr><td>9610506.9</td><td>20 May 1996 (20.05.96)</td><td>GB</td></tr> <tr><td>9623234.3</td><td>7 November 1996 (07.11.96)</td><td>GB</td></tr> <tr><td>9626883.4</td><td>24 December 1996 (24.12.96)</td><td>GB</td></tr> <tr><td>9708071.7</td><td>22 April 1997 (22.04.97)</td><td>GB</td></tr> </table> <p>(71) Applicant (for all designated States except US): CHIRO-SCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): DYKE, Hazel, Joan [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). MONTANA, John, Gary [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).</p> <p>(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).</p>		9610506.9	20 May 1996 (20.05.96)	GB	9623234.3	7 November 1996 (07.11.96)	GB	9626883.4	24 December 1996 (24.12.96)	GB	9708071.7	22 April 1997 (22.04.97)	GB	<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
9610506.9	20 May 1996 (20.05.96)	GB													
9623234.3	7 November 1996 (07.11.96)	GB													
9626883.4	24 December 1996 (24.12.96)	GB													
9708071.7	22 April 1997 (22.04.97)	GB													
<p>(54) Title: QUINOLINE SULFONAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS</p> <p>(57) Abstract</p> <p>A compound of general formula (i), wherein R is H, halogen or alkyl; R₁ represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl; R₂, R₃ and R₄ are the same or different and are each H, R₇, OR₁₁, COR₇, C(-NOR₇)R₇, alkyl-C(-NOR₇)R₇, alkyl-C(-NOH)R₇, C(-NOH)R₇, halogen, CF₃, CN, CO₂H, CO₂R₁₁, CONH₂, CONHR₇, CON(R₇)₂, NR₉R₁₀ or CONR₁₂R₁₃ where NR₁₂R₁₃ is a heterocyclic ring optionally substituted with one or more R₁₅; R₅ represents H, arylalkyl, heteroarylalkyl, S(O)_mR₁₁ or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO₂R₈, SO₂NR₁₂R₁₃, CONR₁₂R₁₃, CN, carbonyl oxygen, NR₉R₁₀, COR₁₁ and S(O)_nR₁₁; R₆ represents aryl, heteroaryl, arylalkyl or heteroarylalkyl. The compounds can be used to treat disease states, for example disease states associated with proteins that mediate cellular activity, for example by inhibiting tumour necrosis factor and/or by inhibiting phosphodiesterase IV.</p> <p style="text-align: center;"> (i) </p> <p style="text-align: center;"> </p>															

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

QUINOLINE SULFONAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS

Field of the Invention

The present invention relates to novel quinolines, and to their formulation and use as pharmaceuticals.

5 Background of the Invention

Japanese Patent Publication 2-184673 discloses quinolinesulphonamides.


US-A-4910193 discloses quinolinesulphonamides, in which the sulphonamide nitrogen is substituted by a variety of bridged saturated ring systems, as medicaments suitable for the treatment of serotonin-induced gastrointestinal disturbances.

10 US-A-4857301 and US-A-5340811 disclose quinolinesulphonamides in the treatment of asthma, respectively as bronchodilators and as anti-allergic compounds.

Phosphodiesterases (PDE) and Tumour Necrosis Factor (TNF), their modes of action and the therapeutic utilities of inhibitors thereof, are described in WO-A-9636595, WO-A-9636596 and WO-A-9636611, the contents of which are incorporated herein by reference. The same documents disclose sulphonamides having utility as PDE and TNF 15 inhibitors.

Summary of the Invention

This invention is based on the discovery of novel compounds that can be used to treat disease states, for example disease states associated with proteins that mediate 20 cellular activity, for example by inhibiting tumour necrosis factor and/or by inhibiting phosphodiesterase IV. According to the invention, the novel compounds are of formula (i):



30

wherein R is H, halogen or alkyl;

R₁ represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl;

R₂, R₃ and R₄ are the same or different and are each H, R₇, OR₁₁, COR₇, C(=NOR₇)R₇, alkyl-C(=NOR₇)R₇, alkyl-C(=NOH)R₇, C(=NOH)R₇, halogen, CF₃, CN, 5 CO₂H, CO₂R₁₁, CONH₂, CONHR₇, CON(R₇)₂, NR₉R₁₀ or CONR₁₂R₁₃ where NR₁₂R₁₃ is a heterocyclic ring (such as morpholine or piperidine) optionally substituted with one or more R₁₅;

R₃ represents H, arylalkyl, heteroarylalkyl, S(O)_nR₁₁ or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO₂R₃, SO₂NR₁₂R₁₃, 10 CONR₁₂R₁₃, CN, carbonyl oxygen, NR₉R₁₀, COR₁₁ and S(O)_nR₁₁;

R₆ represents aryl, heteroaryl, arylalkyl or heteroarylalkyl;
in R₅ and/or R₆, the aryl/heteroaryl portion is optionally substituted with one or more substituents alkyl-R₁₄ or R₁₄:

R₇ represents R₁₁ optionally substituted at any position with (one or more) R₁₆;
15 R₈ represents H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₉ represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxy carbonyl, arylsulphonyl, heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;

R₁₀ represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₁₁ represents alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₁₂ and R₁₃ are the same or different and are each H or R₁₁, or NR₁₂R₁₃ represents 25 a heterocyclic ring as defined above;

R₁₄ represents alkyl (optionally substituted by one or more halogens), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO₂R₈, CONR₁₂R₁₃, SO₂NR₁₂R₁₃, halogen, -CN, 30 -NR₉R₁₀, COR₁₁, S(O)_nR₁₁, or (where appropriate) carbonyl oxygen;

R₁₅ represents alkyl, arylalkyl or heteroarylalkyl;

R_{16} represents alkyl, OH, OR₁₁, NR₉R₁₀, CN, CO₂H, CO₂R₁₁, CONR₁₂R₁₃ or COR₁₁;

m represents 1-2; and

n represents 0-2;

5 and pharmaceutically-acceptable salts.

Combinations of substituents and/or variables are only permissible if such combinations result in stable compounds.

Description of the Invention

Suitable pharmaceutically-acceptable salts are pharmaceutically-acceptable base
10 salts and pharmaceutically-acceptable acid addition salts. Certain of the compounds of formula (i) which contain an acidic group form base salts. Suitable pharmaceutically-acceptable base salts include metal salts, such as alkali metal salts for example sodium salts, or organic amine salts such as that provided with ethylenediamine.

Certain of the compounds of formula (i) which contain an amino group form acid
15 addition salts. Suitable acid addition salts include pharmaceutically-acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically-acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphate, α -ketoglutarate, α -glycerophosphate and glucose-1-phosphate. The pharmaceutically-acceptable salts of the
20 compounds of formula (i) are prepared using conventional procedures.

It will be appreciated by those skilled in the art that some of the compounds of formula (i) may exist in more than one tautomeric form. This invention extends to all tautomeric forms.

It will be appreciated that the compounds according to the invention can contain
25 one or more asymmetrically substituted atoms. The presence of one or more of these asymmetric centers in a compound of formula (i) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers, and diastereoisomers and mixtures including racemic mixtures thereof.

When used herein the term alkyl whether used alone or when used as a part of
30 another group includes straight and branched chain alkyl groups containing up to 6 atoms.

Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.

Aryloxy means an aryl-O- group in which the aryl group is as defined below.

Heteroaryloxy means a heteroaryl-O- group and heterocyclooxy means a heterocyclo-O-group in which the heteroaryl and heterocyclo group are as defined below. Alkylamino means an alkyl-N- group in which the alkyl group is as previously defined, arylamino means aryl-N- and heteroaryl amino means an heteroaryl-N- group (aryl and heteroaryl defined below). Thioalkyl means an alkyl-S-group. Cycloalkyl includes a non-aromatic cyclic or multicyclic ring system of about 3 to 10 carbon atoms. The cyclic alkyl may optionally be partially unsaturated. Aryl indicates carbocyclic radicals containing about 6 to 10 carbon atoms. Arylalkyl means an aryl-alkyl- group wherein the aryl and alkyl are as described herein. Heteroarylalkyl means a heteroaryl-alkyl group and heterocycloalkyl means a heterocyclo-alkyl group. Alkylcarbonyl means an alkyl-CO- group in which the alkyl group is as previously described. Arylcarbonyl means an aryl-CO- group in which the aryl group is as previously described. Heteroarylcarbonyl means a heteroaryl-CO-group and heterocyclocarbonyl means a heterocyclo-CO- group. Arylsulphonyl means an aryl-SO₂- group in which the aryl group is as previously described. Heteroarylsulphonyl means a heteroaryl-SO₂- group and heterocyclosulphonyl means a heterocyclo-SO₂- group. Alkoxy carbonyl means an alkoxy-CO- group in which the alkoxy group is as previously described. Alkylsulphonyl means an alkyl-SO₂- group in which the alkyl group is as previously described. Carbonyl oxygen means a -CO- group. It will be appreciated that a carbonyl oxygen can not be a substituent on an aryl or heteroaryl ring. Carbocyclic ring means about a 5 to about a 10 membered monocyclic or multicyclic ring system which may be saturated or partially unsaturated. Heterocyclo ring means about a 5 to about a 10 membered monocyclic or multicyclic ring system (which may be saturated or partially unsaturated) wherein one or more of the atoms in the ring system is an element other than carbon chosen from amongst nitrogen, oxygen or sulphur atoms. Examples include morpholine and piperidine. Heteroaryl means about a 5 to about a 10 membered aromatic monocyclic or multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur; if desired, a N atom may be in the form of an N-oxide. Heterocyclo means about a 5 to about a 10 membered saturated or partially saturated monocyclic or multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system

is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur. Halogen means fluorine, chlorine, bromine or iodine.

Compounds of the invention are useful for the treatment of TNF mediated disease states. "TNF mediated disease or disease states" means any and all disease states in which 5 TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL-6. A disease state in which IL-1, for instance, is a major component, and whose production or action is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As 10 TNF- β (also known as lymphotoxin) has close structural homology with TNF- α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, both TNF- α and TNF- β are considered to be inhibited by compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically indicated otherwise.

This invention relates to a method for mediating or inhibiting the enzymatic activity 15 or catalytic activity of PDE IV in a mammal in need thereof and for inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof.

PDE IV inhibitors are useful in the treatment of a variety of allergic and 20 inflammatory diseases, including: asthma, chronic bronchitis, chronic obstructive airways disease, atopic dermatitis, atopic eczema, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, psoriasis, Bechet's disease, erythematosis, anaphylactoid purpura nephritis, joint inflammation, arthritis, rheumatoid arthritis and other arthritic conditions such as 25 rheumatoid spondylitis and osteoarthritis, septic shock, sepsis, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatment of diabetes insipidus and conditions associated with cerebral metabolic inhibition, such as cerebral senility, senile dementia (Alzheimer's disease), 30 memory impairment associated with Parkinson's disease, depression and multi-infarct dementia. PDE IV inhibitors are also useful in conditions ameliorated by neuroprotectant activity, such as cardiac arrest, stroke and intermittent claudication. PDE IV inhibitors

may be useful in the treatment of tardive dyskinesia, ischaemia and Huntingdon's disease. Additionally, PDE IV inhibitors could have utility as gastroprotectants. A special embodiment of the therapeutic methods of the present invention is the treatment of asthma.

5 The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (i). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, *Herpes zoster* and *Herpes simplex*.

This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HIV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof.

15 The compounds of this invention may also be used in association with the veterinary treatment of animals, other than humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus
20 (FIV) or other retroviral infection such as equine infectious anaemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.

The compounds of this invention are also useful in treating parasite, yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production *in vivo*. A preferred disease state for treatment is fungal meningitis.

25 Compounds of the invention may also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.


The compounds of formula (i) are preferably in pharmaceutically-acceptable form. By pharmaceutically-acceptable form is meant, *inter alia*, of a pharmaceutically-acceptable
30 level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. A pharmaceutically-

acceptable level of purity will generally be at least 50% excluding normal pharmaceutical additives, preferably 75%, more preferably 90% and still more preferably 95%.

The invention further provides a process for the preparation of a compound of formula (i), in which R₁ etc, m and n are as defined above. It will be appreciated that functional groups such as amino, hydroxyl or carboxyl groups present in the various compounds described below, and which it is desired to retain, may need to be in protected forms before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction sequence. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details, see Protective Groups in Organic Synthesis, Wiley Interscience, TW Greene. Thus the process for preparing compounds of formula (i) in which R₃ contains an -OH comprises of deprotecting (for example by hydrogenolysis or hydrolysis) a compound of formula (i) in which R₃ contains an appropriate -OP wherein P represents a suitable protecting group (e.g. benzyl or acetate).

15 It will be appreciated that where a particular stereoisomer of formula (i) is required, this may be obtained by conventional resolution techniques such as high performance liquid chromatography or the synthetic processes herein described may be performed using the appropriate homochiral starting material.

A process for the preparation of a compound of formula (i) comprises reaction of
an appropriate sulphonyl chloride of formula (ii) with a suitable amine of formula (iii)




30

wherein R_{1a} represents R_1 as defined in relation to formula (i) or a group convertible to R_1 , and $R_{2a}-R_{6a}$ similarly represent R_2-R_6 or groups convertible to R_2-R_6 respectively; and

thereafter, if required, converting any group R_{1a} to R₁ and/or R_{2a} to R₂ and/or R_{3a} to R₃ and/or R_{4a} to R₄ and/or R_{5a} to R₅, and/or converting any group R_{6a} to R₆. The reaction of a sulphonyl chloride of formula (ii) with an amine of formula (iii) may be carried out under any suitable conditions known to those skilled in the art. Preferably, the reaction is carried 5 out in the presence of a suitable base, for example an amine such as triethylamine, preferably in an appropriate solvent such as dichloromethane. In some cases a stronger base, such as sodium hydride, and a polar solvent such as dimethylformamide, will be required.

Sulphonyl chlorides of formula (ii) are either commercially available, previously 10 described compounds or are prepared using standard procedures known to those skilled in the art. For example, a sulphonyl chloride of formula (ii) is conveniently prepared from the appropriate sulphonic acid (iv)


15



20

by treatment with a suitable agent such as thionyl chloride or oxalyl chloride. Alternatively, a sulphonyl chloride of formula (ii) may be prepared by sulphonylation of an appropriate quinoline of formula (v)

25



30 with a suitable sulphonylating agent such as chlorosulphonic acid.

Compounds of formula (v) are either commercially-available, previously described compounds or are prepared using standard procedures known to those skilled in the art.,

For example, quinolines of formula (v) may be conveniently prepared by a Skraup reaction (Z.H. Skraup, Ber. 13:2086 (1880)).

A compound of formula (ia) may also be prepared by reaction of a sulphonyl chloride of formula (ii) with an amine of the formula H_2NR_{5a} (vi), to provide a compound 5 of formula (ia) in which R_{5a} is H, followed by reaction with an appropriate agent of formula $R_{1a}R_{6a}Y$ (vii), wherein R_{1a} - R_{6a} are as defined above and Y represents a suitable leaving group such as halogen. The reaction of a sulphonyl chloride of formula (ii) with an amine of formula (vi) may be carried out under any suitable conditions known to those skilled in the art. Preferably, the reaction is carried out in the presence of a suitable base, 10 for example an amine such as triethylamine, preferably in an appropriate solvent such as dichloromethane. In some cases, a stronger base such as sodium hydride, and a polar solvent such as dimethylformamide, may be required.

The reaction of a compound of formula (ia) in which R_{5a} is H with an agent of formula (vii) may be carried out under any suitable conditions known to those skilled in the art. Preferably, the reaction is carried out using an appropriate base, such as sodium 15 hydride, preferably in an appropriate solvent such as dimethylformamide. Agents of formula (vii) are either commercially available or are prepared using standard procedures known to those skilled in the art. Agent (vii) can be an alkylating agent such as propyl bromide, an acylating agent such as benzoyl chloride or a sulphonylating agent such as 20 methanesulphonyl chloride.

Amines of formulae (iii) and (vi) are commercially available, previously described compounds or are prepared using standard procedures known to those skilled in the art.

A compound of formula (i) may also be prepared by interconversion of other compounds of formula (i). For example, a compound in which R_1 contains an alkoxy group 25 may be prepared by appropriate alkylation of a compound in which R_1 contains a hydroxy group.

Compounds in which R_2 - R_4 contain a CO-alkyl, CO-aryl, CO-heteroaryl, CO-alkylaryl, CO-alkylheteroaryl or CO-alkylheterocyclo group may be prepared from compounds in which R_2 - R_4 contain a CN group, by addition of a suitable organometallic 30 agent (such as a Grignard reagent).

By way of further example, compounds in which R_2 - R_4 contain an oxime may be prepared from compounds in which R_2 - R_4 contain a carbonyl group. This transformation

may be carried out using any appropriate standard conditions known to those skilled in the art. Compounds of formula (i) in which R₂-R₄ contain a carbonyl group may be reduced using standard conditions known to those skilled in the art (for example with sodium borohydride in an appropriate solvent) to provide compounds in which R₂-R₄ contains an alcohol group. Compounds in which R₂-R₄ is alkyl may be prepared by reduction of compounds in which R₂-R₄ is CO-alkyl using standard conditions known to those skilled in the art (for example hydrazine hydrate in the presence of a suitable base in an appropriate solvent). Other transformations may be carried out on compounds of formula (i) in which R₂-R₄ contains a carbonyl group. Such transformations include, but are not limited to, reductive amination and alkylation. Any of the above transformations may be carried out either at the end of the synthesis or on an appropriate intermediate.

A compound of formula (i) or where appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, may be administered *per se* or, preferably, as a pharmaceutical composition also comprising a pharmaceutically-acceptable carrier.

Accordingly, the present invention provides a pharmaceutical composition comprising a compound of formula (i) or where appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, and a pharmaceutically-acceptable carrier.

The active compound may be formulated for administration by any suitable route, the preferred route depending upon the disorder for which treatment is required, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral administration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.

The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc, the compounds of the invention are effective in the treatment of humans.

The compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid

preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.

In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.

5 Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example microcrystalline cellulose, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, 10 polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically-acceptable wetting agents such as sodium lauryl sulphate.

The solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.

15 Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable 20 vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated 25 coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

Compositions may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebuliser, or as a microfine powder for 30 insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 µm, such as from 0.1 to 50 µm, preferably less than 10 µm, for example from 1 to 10 µm, 1 to 5 µm or from

2 to 5 µm. Where appropriate, small amounts of other anti-asthmatics and bronchodilators for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.

5 For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

10 Advantageously, adjuvants such as local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be
15 accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.

20 Compounds of formula (i), or if appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, may also be administered as a topical formulation in combination with conventional topical excipients.

25 Topical formulations may be presented as, for instance, ointments, creams or lotions, impregnated dressings, gels, gel sticks, spray and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. The formulations may contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.

30 Suitable cream, lotion, gel, stick, ointment, spray or aerosol formulations that may be used for compounds of formula (i) or if appropriate a pharmaceutically-acceptable salt thereof, are conventional formulations well known in the art, for example, as described in

standard text books such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, and the British and US Pharmacopoeias.

Suitably, the compound of formula (i), or if appropriate a pharmaceutically-acceptable salt thereof, will comprise from about 0.5 to 20% by weight of the formulation, 5 favourably from about 1 to 10%, for example 2 to 5%.

The dose of the compound used in the treatment of the invention will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and the relative efficacy of the compound. However, as a general guide suitable unit doses may be 0.1 to 1000mg, such as 0.5 to 200, 0.5 to 100 or 0.5 to 10mg, for example 0.5, 1, 2, 3, 4 or 5mg; 10 and such unit doses may be administered more than once a day, for example 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total daily dosage for a 70kg adult is in the range of about 0.1 to 1000mg, that is in the range of about 0.001 to 20 mg/kg/day, such as 0.007 to 3, 0.007 to 1.4, 0.007 to 0.14 or 0.01 to 0.5mg/kg/day, for example 0.01, 0.02, 0.04, 0.05, 0.06, 0.08, 0.1 or 0.2 mg/kg/day, and such therapy may 15 extend for a number of weeks or months.

When used herein the term "pharmaceutically-acceptable" encompasses materials suitable for both human and veterinary use.

The following Examples illustrate the invention.

Intermediate 1 8-Methoxyquinoline-5-(N-benzyl)sulphonamide

20 Triethylamine (0.38ml) was carefully added to a suspension of 8-methoxyquinoline-5-sulphonyl chloride (203mg) in dichloromethane (10ml) at 0°C under nitrogen. Benzylamine (90 µl) was then added and the mixture stirred for 30 minutes at 0°C and 16 hours at room temperature. The reaction was diluted with dichloromethane (30ml), washed with water (15ml) and saturated aqueous sodium chloride (20ml). The 25 organic layer was dried over magnesium sulphate, filtered and the filtrate evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with 2% methanol in dichloromethane to yield the titled compound as a white solid (135mg).

Mp 150-151°C

Example 1 8-Methoxyquinoline-5-(N-benzyl-N-methanesulphonyl)sulphonamide

30 Sodium hydride (120mg, 60% dispersion in oil) was added to a solution of 8-methoxyquinoline-5-(N-benzyl)sulphonamide (120mg) in anhydrous DMF (3ml) at 0°C under nitrogen. The resultant mixture was stirred for 20 minutes and then treated with

methanesulphonyl chloride (34µl). The reaction was stirred for one hour at 0°C and 18 hours at room temperature. Water (1ml) was carefully added and the solvent evaporated *in vacuo*. The residue was partitioned between dichloromethane (20ml) and saturated aqueous sodium hydrogen carbonate solution (10ml). The aqueous layer was extracted 5 with dichloromethane (10ml). The organic extracts were combined and washed with saturated aqueous sodium chloride (10ml), dried over magnesium sulphate, filtered and the filtrate evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with 10% ethyl acetate in dichloromethane to yield the title compound as a white solid (99mg) after trituration with diethyl ether.

10 TLC R_f 0.45 (5% methanol in dichloromethane)
Mp 157-158°C

Example 2 8-Methoxyquinoline-5-(N-benzyl-N-propyl)sulphonamide

The title compound was obtained as a colourless gum (250mg) from 8-methoxyquinoline-5-(N-benzyl)sulphonamide and bromopropane using a similar procedure 15 to that described in Example 1.

TLC R_f 0.1 (50% ethyl acetate in hexane).

Assay methods

The assays used to confirm the phosphodiesterase IV inhibitory activity of compounds of formula (i) are standard assay procedures as disclosed by Schilling *et al*,

20 Anal. Biochem. 216:154 (1994), Thompson and Strada, Adv. Cycl. Nucl. Res. 8:119 (1979) and Gristwood and Owen, Br. J. Pharmacol. 87:91P (1986).

Compounds of formula (i) have exhibited activity at levels consistent with those believed to be useful in treating phosphodiesterase IV-related disease states in those assays.

25 The ability of compounds of formula (i) to inhibit TNF production in human peripheral blood mononuclear cells (PMBC's) is measured as follows. PMBC's are prepared from freshly taken blood or "Buffy coats" by standard procedures. Cells are plated out in RPMI1640 +1% foetal calf serum in the presence and absence of inhibitors. LPS (100 ng/ml) is added and cultures are incubated for 22 h at 37°C in an atmosphere 30 of 95% air/5% CO₂. Supernatants are tested for TNFα by ELISA using commercially available kits.

In vivo activity in a skin eosinophilia model is determined by using the methods described by Hellewell *et al*, Br. J. Pharmacol. 111:811 (1994) and Br. J. Pharmacol. 110:416 (1993). Activity in a lung model is measured using the procedures described by Kallos and Kallos, Int. Archs. Allergy Appl. Immunol. 73:77 (1984), and Sanjar *et al*, Br.

5 J. Pharmacol. 99:679 (1990).


An additional lung model, which allows measurement of inhibition of the early and late-phase asthmatic responses and also the inhibition of airway hyperreactivity, is described by Broadley *et al*, Pulmonary Pharmacol. 7:311 (1994), J. Immunological Methods 190:51 (1996) and British J. Pharmacol. 116:2351 (1995).

10 **Abbreviations**

LPS	Lipopolysaccharide (endotoxin)
ELISA	Enzyme linked immunosorbent assay

CLAIMS

1. A compound of the general formula (i)



5

wherein R is H, halogen or alkyl;

R₁ represents OH, alkoxy optionally substituted with one or more halogens, or

thioalkyl;

R₂, R₃ and R₄ are the same or different and are each H, R₇, OR₁₁, COR₇, C(=NOR₇)R₇, alkyl-C(=NOR₇)R₇, alkyl-C(=NOH)R₇, C(=NOH)R₇, halogen, CF₃, CN, CO₂H, CO₂R₁₁, CONH₂, CONHR₇, CON(R₇)₂, NR₉R₁₀ or CONR₁₂R₁₃ where NR₁₂R₁₃ is a heterocyclic ring optionally substituted with one or more R₁₅;

R₅ represents H, arylalkyl, heteroarylalkyl, S(O)_mR₁₁ or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO₂R₈, SO₂NR₁₂R₁₃,

CONR₁₂R₁₃, CN, carbonyl oxygen, NR₉R₁₀, COR₁₁ and S(O)_nR₁₁;

R₆ represents aryl, heteroaryl, arylalkyl or heteroarylalkyl;

in R₅ and/or R₆, the aryl/heteroaryl portion is optionally substituted with one or more substituents alkyl-R₁₄ or R₁₄;

R₇ represents R₁₁ optionally substituted at any position with one or more R₁₆;

R₈ represents H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₉ represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxy carbonyl, arylsulphonyl, heteroaryl sulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroaryl carbonyl, heterocyclocarbonyl or alkylsulphonyl;

R₁₀ represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₁₁ represents alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₁₂ and R₁₃ are the same or different and are each H or R₁₁, or NR₁₂R₁₃ represents a heterocyclic ring as defined above;

5 R₁₄ represents alkyl (optionally substituted by one or more halogens), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO₂R₈, CONR₁₂R₁₃, SO₂NR₁₂R₁₃, halogen, -CN, -NR₉R₁₀, COR₁₁, S(O)_mR₁₁, or carbonyl oxygen;

10 R₁₅ represents alkyl, arylalkyl or heteroarylalkyl;

R₁₆ represents alkyl, OH, OR₁₁, NR₉R₁₀, CN, CO₂H, CO₂R₁₁, CONR₁₂R₁₃ or COR₁₁;

m is an integer of up to 2; and

n represents 0-2;

15 or a pharmaceutically-acceptable salt thereof.

2. A compound of claim 1, wherein R is H or halogen.

3. A compound of claim 1 or claim 2, wherein R₁ is alkoxy optionally substituted with one or more halogens.

4. A compound of any preceding claim, wherein R₂, R₃, R₄ are the same or different

20 and each represent H, CF₃, COR₁₁, C(=NOR₁₁)R₇, C(=NOH)R₇, CN, R₇, alkyl-C(=NOH), or alkyl-C(=NOR₁₁)R₇.

5. A compound of any preceding claim, wherein R₃ is H, arylalkyl, heteroarylalkyl, S(O)_mR₁₁ or alkyl.

6. A compound of any preceding claim, wherein R₆ is arylalkyl or heteroaryl in which

25 the aryl and heteroaryl portions may be optionally substituted with one or more substituents alkyl-R₁₄ or R₁₄.

7. A compound of claim 1, wherein

R is H;

R₁ is optionally-substituted alkoxy;

30 R₂, R₃ and R₄ are independently H, R₇ or alkyl-R₇;

R₇ is H, OH, alkoxy, aryloxy, heteroaryloxy, heterocyclooxy, arylalkoxy, heteroarylalkoxy, heterocycloalkoxy, alkylamino, CF₃ or R₁₁;

R_4 is H, alkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R_9 is not cycloalkyl;

R_{10} is not cycloalkyl;

R_{11} is not cycloalkyl; and

5 R_{14} is not alkyl, substituted alkoxy, thioalkyl, or cycloalkyl.

8. A compound of claim 1, which is
8-methoxyquinoline-5-(N-benzyl-N-methanesulphonyl)sulphonamide.

9. A compound of claim 1, which is
8-methoxyquinoline-5-(N-benzyl-N-propyl)sulphonamide.

10 10. A compound of any preceding claim, in the form of an enantiomer or mixture of enantiomers.

11. A pharmaceutical composition for therapeutic use comprising a compound of any preceding claim and a pharmaceutically-acceptable carrier or excipient.

12. Use of a compound of any of claims 1 to 10, for the manufacture of a medicament

15 13. for use in the treatment of a disease state capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor.

13. The use of claim 12, wherein the disease state is a pathological condition associated with a function of phosphodiesterase IV, eosinophil accumulation or a function of the eosinophil.

20 14. The use of claim 13, wherein the pathological condition is selected from asthma, chronic bronchitis, chronic obstructive airways disease, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, psoriasis, rheumatoid arthritis, gouty arthritis and other arthritic conditions, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome, diabetes insipidus, keratosis, atopic eczema, atopic dermatitis, cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, depression, cardiac arrest, stroke and intermittent claudication.

25 15. The use of claim 13, wherein the pathological condition is selected from chronic bronchitis, allergic rhinitis and adult respiratory distress syndrome.

30 16. The use of claim 12, wherein the disease state is capable of being modulated by TNF inhibition.

17. The use of claim 16, wherein the disease state is an inflammatory disease or autoimmune disease.
18. The use of claim 17, wherein the disease state is selected from joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis and osteoarthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, asthma, bone resorption diseases, reperfusion injury, graft vs host reaction, allograft rejection, malaria, myalgias, HIV, AIDS, ARC, cachexia, Crohn's disease, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes mellitus, psoriasis, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukaemia.
19. The use of claim 14 or claim 18, wherein the pathological condition or disease state is asthma.
20. The use of claim 18, wherein the disease state is acute respiratory distress syndrome, pulmonary inflammatory disease or pulmonary sarcoidosis.
21. The use of claim 18, wherein the disease state is joint inflammation.
22. The use of claim 13 or claim 17, wherein the disease state is a disease or disorder of the brain, such as brain trauma, stroke, ischaemia, Huntingdon's disease or tardive dyskinesia.
23. The use of claim 16, wherein the disease state is a yeast or fungal infection.
24. Use of a compound of any of claim 1 to 10, for the manufacture of a medicament for use in gastropreservation.
25. Use of a compound of any of claims 1 to 10, for the manufacture of a medicament for use as an analgesic, anti-tussive or anti-hyperalgesic in the treatment of neurogenic inflammatory disease associated with irritation and pain.
26. Use of a compound of any of claims 1 to 10, in coadministration with another drug such as a bronchodilator, steroid or xanthine, for asthma therapy.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/01360

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D215/36 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 116, no. 12, 30 March 1992 Columbus, Ohio, US; abstract no. 128690f, KAIJIWARA, AKIO ET AL: "Preparation of quinolinesulfonamide ..." XP002025490 * RN 139413-30-2, 139390-29-7, 139390-28-6, -27-5, -26-4, -25-3, -24-2, -23-1, -22-0, -21-9, -20-8 * see abstract & JP 03 258 763 A (AQSAHI CHEMICAL INDUSTRY CO., LTD.)</p> <p>---</p> <p>-/-</p>	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
4 September 1997	23.09.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patendaan 2 NL - 2200 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Van Bijlen, H

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inte...inal Application No
PCT/GB 97/01360

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 114, no. 1, 7 January 1991 Columbus, Ohio, US; abstract no. 6308a, AO, EIBOKU ET AL: "Preparation of (iso)quinolinesulfonamides as ..." XP002025491 * RN 130998-17-3 * see abstract & JP 02 184 673 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) ---	1
X	CHEMICAL ABSTRACTS, vol. 113, no. 18, 29 October 1990 Columbus, Ohio, US; abstract no. 164723r, TOCHILKIN, A.I. ET AL: "8-Methoxy-5-quinolinesulfonyl chloride , a ..." XP002025492 * RN 129660-52-2, -51-1, -50-0, -49-7 * see abstract & BIOORG. KHIM., vol. 16, no. 7, - 1990 pages 956-962. ---	1
X	CHEMICAL ABSTRACTS, vol. 51, no. 3, 1957 Columbus, Ohio, US; abstract no. 15005a3, PAUL E. THOMPSON ET AL: "Antiamoebic action of ..." XP002039759 * RN 100880-86-2 * see abstract & AM. J. TROP. MED. HYG. , vol. 4, - 1955 pages 224-248. ---	1
X	CHEMICAL ABSTRACTS, vol. 106, no. 16, 20 April 1987 Columbus, Ohio, US; abstract no. 129242s, OKI, NOBUTAKA: "Silver halide color ..." XP002039760 * RN 107317-05-5 * see abstract & JP 61 169 845 A (FUJI PHOTO FILM CO., LTD.) ---	1
1		-/-

Form PCT/ISA/218 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/01360

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 122, no. 8, 20 February 1995 Columbus, Ohio, US; abstract no. 95157f, IBRAHIM,S.A. ET AL: "Antimicrobial quinolinol-5-sulfonamide ..." XP002039761 * RN 105049-37-4 * see abstract & BULL. FAC. SCI.,ASSIUT UNIV..B, vol. 22, no. 2, - 1993 pages 101-108, ***	1
X	CHEMICAL ABSTRACTS, vol. 100, no. 8, 20 February 1984 Columbus, Ohio, US; abstract no. 60857c, TIWARI,G.D. ET AL: "Studies on the ..." XP002039762 * RN 76819-01-7 * see abstract & J. INDIAN CHEM. SOC., vol. 60, no. 7, - 1983 pages 698-699, ***	1
A	WO 94 22852 A (SYNTEX(U.S.A.)INC.) 13 October 1994 see claims ***	1,11,12
A	WO 95 03051 A (PHARMACIA AB) 2 February 1995 see claims ***	1,11,12
P,A	WO 96 36611 A (CHIROSCIENCE LTD.) 21 November 1996 see claims ****	1,11,12
		1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter Application No
PCT/GB 97/01360

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9422852 A	13-10-94	US 5455252 A		03-10-95
		AU 679222 B		26-06-97
		AU 6412994 A		24-10-94
		CA 2159603 A		13-10-94
		EP 0691966 A		17-01-96
		FI 954651 A		29-09-95
		HU 9500111 A		28-06-95
		HU 73181 A		28-06-96
		JP 8511238 T		26-11-96
		NO 953879 A		22-11-95
-----	-----	-----	-----	-----
WO 9503051 A	02-02-95	AU 7278294 A		20-02-95
		EP 0711165 A		15-05-96
		JP 9500640 T		21-01-97
		ZA 9404238 A		16-02-95
-----	-----	-----	-----	-----
WO 9636611 A	21-11-96	AU 5772196 A		29-11-96
-----	-----	-----	-----	-----